Compare · GILD vs INTS
GILD vs INTS
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Intensity Therapeutics Inc. (INTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and INTS operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 12985.9x INTS ($12.8M).
- Over the past year, GILD is up 24.0% and INTS is down 40.8% - GILD leads by 64.7 points.
- INTS has been more active in the news (5 items in the past 4 weeks vs 4 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 0 for INTS).
- Company
- Gilead Sciences Inc.
- Intensity Therapeutics Inc.
- Price
- $134.23-1.50%
- $4.74-3.46%
- Market cap
- $166.72B
- $12.8M
- 1M return
- +5.49%
- +26.06%
- 1Y return
- +23.95%
- -40.75%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2023
- News (4w)
- 4
- 5
- Recent ratings
- 25
- 0
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest INTS
- Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
- SEC Form S-8 filed by Intensity Therapeutics Inc.
- Principal Accounting Officer Wesolowski John M was granted 3,688 shares, increasing direct ownership by 108% to 7,102 units (SEC Form 4)
- Chief Financial Officer Talamo Joseph was granted 1,093 shares, increasing direct ownership by 95% to 2,239 units (SEC Form 4)
- Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
- Intensity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
- Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 10-Q filed by Intensity Therapeutics Inc.